SCHEDULE 13D/A: Pfizer Reduces Haleon Stake to 7.3% Following $3 Billion Secondary Offering

Pfizer Inc. has significantly reduced its beneficial ownership in Haleon plc to approximately 7.3% after completing a secondary offering of 700 million Ordinary Shares, generating substantial proceeds.

Summary

• Pfizer Inc. filed Amendment No. 12 to its Schedule 13D, updating its beneficial ownership in Haleon plc.
• As of January 17, 2025, following the January 2025 Secondary Offering, Pfizer's beneficial ownership in Haleon plc stands at 661,709,764 Ordinary Shares, representing approximately 7.3% of Haleon's outstanding shares.
• This ownership comprises 197,228,952 Restricted American Depository Shares (representing 394,457,904 Ordinary Shares) and 267,251,860 Ordinary Shares held by Pfizer's nominee.
• The beneficial ownership percentage is calculated based on 9,053,360,882 Ordinary Shares of Haleon outstanding as of October 31, 2024.
• Pfizer, as the seller, completed a secondary block trade agreement on January 14, 2025, with several lead managers including J.P. Morgan Securities plc and Morgan Stanley & Co. International plc.
• Through this offering, 700,000,000 Ordinary Shares of Haleon were sold at a price of 357 pence per Ordinary Share, which was approximately $4.36 per share at the time of pricing.
• The January 2025 Secondary Offering closed on January 17, 2025.
• Pfizer has agreed to a lock-up period, restricting further sales of Haleon equity securities for 60 days following the closing of the secondary offering, starting January 14, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. For Pfizer, it represents successful monetization of a non-core asset. For Haleon, it reduces the overhang of a large shareholder's stake, potentially improving market dynamics, despite the short-term dilution effect of the large block sale.

Positives

• Pfizer successfully monetized a significant portion of its non-core asset in Haleon, providing capital that can be deployed elsewhere.
• The completion of the secondary offering reduces the overhang of a large institutional shareholder's potential future sales on Haleon's stock, potentially improving market sentiment and liquidity for Haleon shares.
• The transaction was executed through an accelerated book building process, indicating strong market demand for Haleon shares at the specified price.

Negatives

• The sale of a large block of shares by a major shareholder like Pfizer could exert downward pressure on Haleon's stock price in the short term due to increased supply.
• The reduction in Pfizer's stake means less direct alignment between Pfizer's strategic interests and Haleon's future performance.

Risks

• The 60-day lock-up period prevents Pfizer from selling additional Haleon shares, but once it expires, there is a potential for further sales, which could create future share price volatility for Haleon.
• Market conditions or investor sentiment could impact the value of Pfizer's remaining stake in Haleon.

Future Outlook

Pfizer is subject to a 60-day lock-up period, preventing further sales of Haleon equity securities until approximately mid-March 2025. This indicates a temporary pause in Pfizer's divestment strategy regarding its remaining stake in Haleon.

Industry Context

This secondary offering by Pfizer is consistent with the broader trend of large pharmaceutical companies divesting non-core assets, particularly consumer healthcare divisions, to focus on their core pharmaceutical research and development. It follows the spin-off of Haleon from GSK and Pfizer's subsequent gradual reduction of its stake, aiming to streamline operations and optimize capital allocation.

Related Party Transactions

• The secondary offering itself can be considered a related party transaction, as Pfizer was a significant shareholder of Haleon following the spin-off, and this transaction involves the sale of its stake.

Stakeholder Impact

• **Haleon Shareholders**: Increased free float and potential removal of a significant share overhang, which could lead to improved liquidity and potentially a more stable share price in the long term. Short-term price volatility due to the large block sale is possible.
• **Pfizer Shareholders**: Monetization of a non-core asset, providing capital for Pfizer's strategic priorities, such as investments in its core pharmaceutical business or debt reduction.

Next Steps

• Pfizer will adhere to the 60-day lock-up period, which restricts further sales of Haleon equity securities until approximately mid-March 2025.

Key Dates

Recommendation

Keywords

Haleon plc, Pfizer Inc., Secondary Offering, Share Sale, Beneficial Ownership, Schedule 13D/A, Consumer Healthcare, Divestment, Equity Markets, Lock-up Period